Piper Sandler Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR)

Piper Sandler began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a note issued to investors on Friday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $72.00 price target on the stock. Piper Sandler’s price target suggests a potential upside of 184.02% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Rodman & Renshaw initiated coverage on Monopar Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $50.00 price objective on the stock. HC Wainwright upped their price objective on Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 11th.

Monopar Therapeutics Stock Up 3.6 %

Shares of MNPR opened at $25.35 on Friday. The business’s 50 day moving average price is $21.84 and its 200-day moving average price is $10.74. Monopar Therapeutics has a 52 week low of $1.54 and a 52 week high of $38.50. The stock has a market cap of $133.80 million, a P/E ratio of -12.87 and a beta of 1.23.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. On average, equities analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling at Monopar Therapeutics

In related news, CFO Karthik Radhakrishnan bought 1,550 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was acquired at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the purchase, the chief financial officer now owns 1,550 shares in the company, valued at approximately $25,187.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.